These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 33206174)

  • 61. Checkpoint kinase 1 is essential for fetal and adult hematopoiesis.
    Schuler F; Afreen S; Manzl C; Häcker G; Erlacher M; Villunger A
    EMBO Rep; 2019 Aug; 20(8):e47026. PubMed ID: 31379128
    [TBL] [Abstract][Full Text] [Related]  

  • 62. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
    Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
    Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
    Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.
    Wang JN; Che Y; Yuan ZY; Lu ZL; Li Y; Zhang ZR; Li N; Li RD; Wan J; Sun HD; Sun N; Puno PT; He J
    Toxicol Appl Pharmacol; 2019 Feb; 365():71-83. PubMed ID: 30633885
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 66. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.
    Cole KA; Huggins J; Laquaglia M; Hulderman CE; Russell MR; Bosse K; Diskin SJ; Attiyeh EF; Sennett R; Norris G; Laudenslager M; Wood AC; Mayes PA; Jagannathan J; Winter C; Mosse YP; Maris JM
    Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3336-41. PubMed ID: 21289283
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
    Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
    Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
    Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
    Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.
    Simmons JK; Michalowski AM; Gamache BJ; DuBois W; Patel J; Zhang K; Gary J; Zhang S; Gaikwad S; Connors D; Watson N; Leon E; Chen JQ; Kuehl WM; Lee MP; Zingone A; Landgren O; Ordentlich P; Huang J; Mock BA
    Mol Cancer Ther; 2017 Sep; 16(9):2008-2021. PubMed ID: 28522584
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
    Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
    Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma.
    Borankova K; Krchniakova M; Leck LYW; Kubistova A; Neradil J; Jansson PJ; Hogarty MD; Skoda J
    Cell Death Dis; 2023 Nov; 14(11):747. PubMed ID: 37973789
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
    Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
    Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation.
    Blackburn JS; Liu S; Wilder JL; Dobrinski KP; Lobbardi R; Moore FE; Martinez SA; Chen EY; Lee C; Langenau DM
    Cancer Cell; 2014 Mar; 25(3):366-78. PubMed ID: 24613413
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo.
    Zhang X; Geng L; Yang L; Wang Y; Zou Z; Zhang Y; Xu H; Lei H; Cao Y; Wu Y; Gu W; Zhou L
    Cell Signal; 2023 Oct; 110():110837. PubMed ID: 37544636
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis.
    Borga C; Park G; Foster C; Burroughs-Garcia J; Marchesin M; Shah R; Hasan A; Ahmed ST; Bresolin S; Batchelor L; Scordino T; Miles RR; Te Kronnie G; Regens JL; Frazer JK
    Leukemia; 2019 Feb; 33(2):333-347. PubMed ID: 30111845
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.
    Murga M; Campaner S; Lopez-Contreras AJ; Toledo LI; Soria R; Montaña MF; Artista L; Schleker T; Guerra C; Garcia E; Barbacid M; Hidalgo M; Amati B; Fernandez-Capetillo O
    Nat Struct Mol Biol; 2011 Nov; 18(12):1331-1335. PubMed ID: 22120667
    [TBL] [Abstract][Full Text] [Related]  

  • 79. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
    Roderick JE; Tesell J; Shultz LD; Brehm MA; Greiner DL; Harris MH; Silverman LB; Sallan SE; Gutierrez A; Look AT; Qi J; Bradner JE; Kelliher MA
    Blood; 2014 Feb; 123(7):1040-50. PubMed ID: 24394663
    [TBL] [Abstract][Full Text] [Related]  

  • 80. WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia.
    Hu J; Wang T; Xu J; Wu S; Wang L; Su H; Jiang J; Yue M; Wang J; Wang D; Li P; Zhou F; Liu Y; Qing G; Liu H
    Haematologica; 2021 Jul; 106(7):1816-1827. PubMed ID: 31919076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.